Please check your internet connection and try again.
## Overview
Mylotat is a brand name for **Atropine Sulfate**. Atropine is an anticholinergic medication that blocks the effects of acetylcholine.
## Primary Indications
* Bradycardia (symptomatic)
* Organophosphate poisoning (antidote)
* Preoperative medication (to reduce secretions and prevent bradycardia)
* Ophthalmic uses (mydriasis, cycloplegia) - *Note: Ophthalmic preparations are for topical use only and not for systemic administration.*
## Adult Dosing
* **Symptomatic Bradycardia:**
* 0.5 mg IV/IO every 3-5 minutes.
* Maximum total dose: Not strictly defined, but typically no more than 3 mg is recommended in cardiac arrest guidelines. Higher doses may be used in specific, non-arrest settings like organophosphate poisoning.
* **Organophosphate Poisoning:** Dosing is highly variable and depends on severity. Larger doses are often required. Consult poison control or specialized protocols.
* **Preoperative:** 0.4 mg to 0.6 mg SC, IM, or IV 30-60 minutes before surgery.
## Pediatric Dosing
* **Symptomatic Bradycardia:**
* **< 1 year:** 0.02 mg/kg IV/IO, minimum dose 0.1 mg, maximum dose 0.5 mg per dose. Repeat every 3-5 minutes.
* **1-5 years:** 0.04 mg/kg IV/IO, minimum dose 0.1 mg, maximum dose 1 mg per dose. Repeat every 3-5 minutes.
* **6-12 years:** 0.04 mg/kg IV/IO, minimum dose 0.1 mg, maximum dose 2 mg per dose. Repeat every 3-5 minutes.
* **Adolescents (≥13 years):** Dosing as per adults (0.5 mg IV/IO every 3-5 minutes).
* **Organophosphate Poisoning:** Consult pediatric poison control or specialized protocols. Dosing is highly variable.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is typically recommended, but caution is advised as elimination may be prolonged.
* **Hepatic Impairment:** No specific dose adjustment is typically recommended.
* **Elderly:** May be more sensitive to anticholinergic effects; use with caution.
## Contraindications
* Known hypersensitivity to atropine.
* Untreated narrow-angle glaucoma (ophthalmic use).
* Tachycardia.
* Glaucoma (systemic use may worsen).
* Certain gastrointestinal or genitourinary obstructions.
## Adverse Effects
Common anticholinergic effects: Dry mouth, blurred vision, photophobia, dry skin, urinary retention, constipation, increased heart rate (tachycardia), confusion, dizziness, drowsiness. Less common: Fever, nausea, vomiting, abdominal distension. Severe: Hallucinations, delirium, respiratory depression, coma.
## Key Drug Interactions
* **Other Anticholinergics:** Additive anticholinergic effects.
* **Prokinetic Agents (e.g., Metoclopramide):** May decrease efficacy.
* **Potassium Chloride:** Oral potassium chloride can cause GI ulcerations, which may be exacerbated by atropine's effect of slowing GI motility.
## Monitoring
* Heart rate and rhythm.
* Blood pressure.
* Level of consciousness.
* Urinary output.
* Bowel sounds.
* Signs of anticholinergic toxicity (e.g., flushed skin, dry mucous membranes, mydriasis, confusion).
## Clinical Pearls
* Atropine is not effective for bradycardia due to hypoxemia or AV block Mobitz II/complete heart block.
* In organophosphate poisoning, atropine needs to be administered in large, repeated doses until signs of atropinization occur (e.g., dry mouth, blurred vision, tachycardia).
* IV administration results in a rapid onset of action (within minutes).
* Use with caution in patients with conditions that may be aggravated by anticholinergic effects (e.g., prostatic hypertrophy, obstructive lung disease).
---
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and specific patient factors before making any treatment decisions. Dosing may vary based on local protocols and clinical judgment.
